S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
NASDAQ:ARTL

Artelo Biosciences (ARTL) Stock Price, News & Analysis

$1.32
+0.04 (+2.73%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$1.28
$1.39
50-Day Range
$1.28
$1.73
52-Week Range
$1.15
$2.98
Volume
6,100 shs
Average Volume
16,099 shs
Market Capitalization
$4.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Artelo Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
280.2% Upside
$5.00 Price Target
Short Interest
Healthy
0.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.07) to ($1.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

ARTL stock logo

About Artelo Biosciences Stock (NASDAQ:ARTL)

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

ARTL Stock Price History

ARTL Stock News Headlines

Recap: Artelo Biosciences Q4 Earnings
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Artelo Biosciences Inc ARTL
Artelo Biosciences (ARTL) Gets a Buy from Maxim Group
Artelo Biosciences (ARTL) Gets a Buy from Ladenburg Thalmann & Co.
Artelo Biosciences GAAP EPS of -$3.56
See More Headlines
Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/25/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARTL
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+280.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.12 per share

Miscellaneous

Free Float
3,005,000
Market Cap
$4.24 million
Optionable
Not Optionable
Beta
1.45
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


ARTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Artelo Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARTL shares.
View ARTL analyst ratings
or view top-rated stocks.

What is Artelo Biosciences' stock price target for 2024?

1 brokerages have issued 12-month target prices for Artelo Biosciences' shares. Their ARTL share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 280.2% from the stock's current price.
View analysts price targets for ARTL
or view top-rated stocks among Wall Street analysts.

How have ARTL shares performed in 2024?

Artelo Biosciences' stock was trading at $1.40 at the beginning of 2024. Since then, ARTL shares have decreased by 6.1% and is now trading at $1.3150.
View the best growth stocks for 2024 here
.

Are investors shorting Artelo Biosciences?

Artelo Biosciences saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 14,500 shares, a decline of 28.2% from the March 15th total of 20,200 shares. Based on an average trading volume of 16,800 shares, the short-interest ratio is currently 0.9 days. Approximately 0.5% of the company's shares are sold short.
View Artelo Biosciences' Short Interest
.

When is Artelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ARTL earnings forecast
.

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) announced its quarterly earnings data on Monday, March, 25th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.70.

When did Artelo Biosciences' stock split?

Artelo Biosciences shares reverse split on the morning of Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).

How do I buy shares of Artelo Biosciences?

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARTL) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners